AHFS Drug Information (AHFS DI) is a leading source of evidence-based drug information.

AHFS DI is a dependable, comprehensive and objective database for FDA approved drug products. Inclusion of evidence-based data on labelled and unlabelled drug use makes this a valuable reference for healthcare professionals seeking to provide their patients with safe and effective therapy.

AHFS DI is published by the American Society of Health-System Pharmacists (ASHP).

SubscribeContent Updates
Features and Benefits icon

Comprehensive: Highly detailed monographs with extensive information on the chemistry and clinical application of all FDA approved drugs

Features and Benefits icon

Evidence-based: Built on evidence from primary sources and peer reviewed by over 500 pharmacists, physicians and healthcare professionals

Features and Benefits icon

Dependable: Fast and easy access to content that is revalidated, revised and updated regularly as new information arrives

Features and Benefits icon

Objective: The information is compiled without any influence from manufacturers, insurers, regulators or other interested parties

Publication Updates

13 Aug
AHFS Drug Information logo
AHFS August 2019 Update

This update contains 4 new monographs and 26 revised monographs.

New monographs: Ropivacaine; Ketamine; Alpelisib; Brexanolone

Revised monographs: Nitazoxanide; Vaccinia Immune Globulin IV; Tapentadol; Fidaxomicin; Letermovir; Ozenoxacin; Burosumab-twza; Dehydrated Alcohol; Patisiran; Galcanezumab-gnlm; Gilteritinib; HYDROcodone; HYDROmorphone; Levorphanol; Codeine; Meperidine; oxyCODONE; Chloramphenicol; Flucytosine; Pentazocine; Levodopa/Carbidopa; Benzocaine; Butorphanol; Local Anesthetics, Parenteral, General Statement; Nicotine; traMADol

09 Jul
AHFS Drug Information logo
AHFS July 2019 Update

This update contains 3 new monographs, 50 revised monographs, and 3 new MedWatch alerts.

New monographs: Risankizumab-rzaa; Tafamidis; Thyrotropin Alfa

Revised monographs: Bosentan; Tinidazole; Eszopiclone; Retapamulin; Eculizumab; Vemurafenib; Dabrafenib; Trametinib Dimethyl Sulfoxide; Pembrolizumab; Cobimetinib; Atezolizumab; Antihemophilic Factor (Recombinant), Fc fusion protein; Antihemophilic Factor (Recombinant), Porcine Sequence; Factor IX (Recombinant), albumin fusion protein; Factor IX (Recombinant), Fc fusion protein; Vestronidase Alfa-vjbk; Factor Xa (recombinant), Inactivated-zhzo; Binimetinib; Encorafenib; Antihemophilic Factor (recombinant), PEGylated-aucl; Megestrol; Antihemophilic Factor (Human); Busulfan; DAUNOrubicin; Lomustine; Loxapine; Mitotane; mitoMYcin; Spironolactone; Mercaptopurine; Dacarbazine; Thiotepa; vinCRIStine; vinBLAStine; Chlorambucil; CISplatin; Streptozocin; Etoposide; Leuprolide; Digoxin Immune Fab; Mupirocin; Fludarabine; Pentostatin; Zolpidem; Antihemophilic Factor (Recombinant); CARBOplatin; Ifosfamide; PACLitaxel; Doxercalciferol; Zaleplon

New MedWatch alerts on the following monographs: Eszopiclone; Zolpidem; Zaleplon

11 Jun
AHFS Drug Information logo
AHFS Drug Information June 2019 Update

This update contains 6 new monographs, 54 revised monographs, 3 discontinued monographs and 1 new MedWatch alert.

New monographs: Siponimod; Calaspargase Pegol-mknl; Dolutegravir And Lamivudine; Cladribine; Romosozumab-aqqg; Erdafitinib

Revised monographs: Valrubicin; Eplerenone; ARIPiprazole; Teriparatide; Natalizumab; IncobotulinumtoxinA; Parathyroid Hormone; Raxibacumab; Venetoclax; Obiltoxaximab; Anthrax Immune Globulin IV (Human); Abaloparatide; Selenious Acid; Secnidazole; Benznidazole; Bictegravir, Emtricitabine, and Tenofovir Alafenamide; Tafenoquine (Arakoda); Zirconium Cyclosilicate; Tecovirimat; Sarecycline; Tafenoquine (Krintafel); Fluorouracil; Floxuridine; Methotrexate; Carmustine; Cyclophosphamide; Procarbazine;Thioguanine; Bleomycin; azaTHIOprine; Melphalan; DOXOrubicin; Cytarabine; Mechlorethamine; DACTINomycin; Sodium Nitroprusside; Prazosin; HydrALAZINE; Diazoxide; Phentolamine; Triamterene; Nitroglycerin; Liotrix; Minoxidil; Furosemide; Rauwolfia Alkaloids; Nitrates and Nitrites General Statement; Bumetanide; Doxazosin; Terazosin; Isradipine; niCARdipine; Capecitabine; Sildenafil

Discontinued monographs: Aripiprazole tablets with sensor; Chloral hydrate; Polythiazide 

New MedWatch alerts on the following monographs: Venetoclax

14 May
AHFS Drug Information logo
AHFS May 2019 Update

This update contains 3 new monographs, 31 revised monographs and 1 new MedWatch alerts.

New monographs: Triclabendazole, Esketamine Hydrochloride, Cetirizine Hydrochloride

Revised monographs: Fondaparinux, Palonosetron, OnabotulinumtoxinA, guanFACINE, Tofacitinib, Mechlorethamine, AbobotulinumtoxinA, IncobotulinumtoxinA, RimabotulinumtoxinB, Mepolizumab, Netupitant/Palonosetron, Obeticholic Acid, Netarsudil, Ibalizumab-uiyk, Erenumab-aooe,
Fremanezumab-vfrm, Galcanezumab-gnlm, aMILoride, Methyldopa, Chlorothiazide, Nystatin, Potassium Supplements, Ethacrynic Acid, Felodipine, Fosinopril, Quinapril, Torsemide, Moexipril, Nisoldipine, Trandolapril, Perindopril

New MedWatch alerts on the following monographs: Febuxostat

09 Apr
AHFS Drug Information logo
AHFS April 2019 Update

This update contains 4 new monographs, 30 revised monographs and 1 new MedWatch alerts.

New monographs: Tafenoquine; Rifamycin; Caplacizumab-yhdp; PrabotulinumtoxinA-xvfs

Revised monographs: Paricalcitol; Eprosartan; Telmisartan; Febuxostat; Factor IX (Recombinant), albumin fusion protein; Factor X (Human); Cobicistat; Calcifediol; Trientine; Benralizumab; Tezacaftor and Ivacaftor; Tafenoquine; Sarecycline; cloNIDine; penicillAMINE; Ergocalciferol; Calcitriol; Propranolol; Methylene Blue; Metoprolol; Vitamin D Analogs General Statement; Timolol; Pindolol; Labetalol; Acebutolol; Esmolol; Bisoprolol; Betaxolol; Carvedilol; Doxercalciferol

New MedWatch alerts on the following monographs: Febuxostat

12 Mar
AHFS Drug Information logo
AHFS March 2019 Update

This update contains 4 new monographs, 35 revised monographs, 9 discontinued monographs and 6 new MedWatch alerts.

New monographs: Prucalopride; Ravulizumab-cwvz; Amifampridine; Tagraxofusp-erzs

Revised monographs: Moxifloxacin; Cevimeline; Gemifloxacin; Ambrisentan; Nebivolol; Liraglutide; Pitavastatin; Azilsartan; Canagliflozin; Riociguat; Sofosbuvir; Dapagliflozin; Pembrolizumab; Empagliflozin; Atezolizumab; Delafloxacin; Copanlisib; Pilocarpine; Magnesium Sulfate; Chlorthalidone; metOLazone; Methyclothiazide; hydroCHLOROthiazide; Bendroflumethiazide; Nadolol; Nystatin; Calcium Salts; Indapamide; Ciprofloxacin; ASHP Guidelines on Handling Hazardous Drugs; Ofloxacin; Fosfomycin; Azithromycin; levoFLOXacin; tiaGABine Hydrochloride 

Discontinued monographs: Telithromycin; telbivudine; albiglutide; dasabuvir, ombitasvir, paritaprevir, and ritonavir; ombitasvir, paritaprevir, and ritonavir; erythromycin estolate; insulin zinc; nystatin; ticarcillin and clavulanate 

New MedWatch alerts on the following monographs: moxifloxacin; gemifloxacin; delafloxacin; ciprofloxacin; ofloxacin; levofloxacin

View more View all content updates